Immunovant is now emphasizing its drug IMVT-1402, which has shown promising results in treating difficult rheumatoid arthritis, with 72.7% of patients responding well by week 16. The company has a strong financial position and believes it can sustain operations through upcoming clinical trial results. IMVT-1402 could potentially treat multiple autoimmune conditions, making it a valuable asset if future data confirms its effectiveness. Despite clinical risks, Immunovant is considered a speculative buy due to IMVT-1402's broad potential.
Photronics, Inc. is under investigation by Glancy Prongay Wolke & Rotter LLP for possible securities law violations following its Q2 2026 earnings report. The company reported a revenue decline to $209 million and a drop in operating margins to 20.1%...
Shell plc announced that as of May 29, 2026, it has 5,586,155,889 ordinary shares outstanding, each with a nominal value of €0.07. The company holds no shares in treasury, and this figure includes shares bought back but not yet cancelled under its sh...
Aduro Clean Technologies announced its participation in several major industry and investor conferences in June 2026, including events in London, Toronto, Frankfurt, and Pittsburgh. The company will showcase its Hydrochemolytic™ Technology and discus...
Aduro Clean Technologies announced its participation in several investor and industry conferences in June 2026, including events in London, Toronto, Frankfurt, and Pittsburgh. The company will showcase its Hydrochemolytic™ technology, discuss progres...
After Palantir's Q1 earnings report, analysts sharply disagree on its valuation, with price targets ranging from $90 to $230. The divide reflects contrasting views on Palantir's AI software platform and growth potential. Bulls see durable government ...
